Last reviewed · How we verify
Cycloferon
Cycloferon is a Small molecule drug developed by POLYSAN Scientific & Technological Pharmaceutical Company. It is currently in Phase 3 development. Also known as: Meglumine acridоnacetate.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cycloferon |
|---|---|
| Also known as | Meglumine acridоnacetate |
| Sponsor | POLYSAN Scientific & Technological Pharmaceutical Company |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza (PHASE3)
- An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer (PHASE2)
- Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cycloferon CI brief — competitive landscape report
- Cycloferon updates RSS · CI watch RSS
- POLYSAN Scientific & Technological Pharmaceutical Company portfolio CI
Frequently asked questions about Cycloferon
What is Cycloferon?
Who makes Cycloferon?
Is Cycloferon also known as anything else?
What development phase is Cycloferon in?
Related
- Manufacturer: POLYSAN Scientific & Technological Pharmaceutical Company — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Meglumine acridоnacetate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing